Trends in Diabetes Medication Taking and Incidence of Depression in Patients with Type 2 Diabetes: A Retrospective Cohort Study from 2010 to 2018.

Publisher: Informa Healthcare Country of Publication: England NLM ID: 9421097 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-7558 (Electronic) Linking ISSN: 10705503 NLM ISO Abbreviation: Int J Behav Med Subsets: MEDLINE

Publication: London : Informa Healthcare
Original Publication: Hillsdale, NJ : Lawrence Erlbaum Associates, c1994-

Diabetes Mellitus, Type 2*/complications ; Diabetes Mellitus, Type 2*/drug therapy ; Diabetes Mellitus, Type 2*/epidemiology; Humans ; Aged ; United States/epidemiology ; Retrospective Studies ; Depression/epidemiology ; Depression/complications ; Incidence ; Medicare ; Risk Factors

Background: This study examined the trends in diabetes medication taking and its association with the incidence of depression in patients with type 2 diabetes (T2D).
Method: A retrospective cohort of Medicare enrollees with regular care in 2010 was defined from 100% Texas Medicare claims. The impact of medication taking on incident depression was evaluated from 2010 to 2018. Cox proportional hazards regressions were used to estimate the association between medication taking and depression.
Results: A total of 72,461 patients with T2D and with regular care were analyzed. Among 60,216 treated patients, the regular medication taking rate slightly increased from 60.8 to 63.2% during the study period. Patients with regular medication taking at baseline had a 9% lower risk of developing depression (hazard ratio [HR]: 0.91, 95% confidence interval [CI]: 0.89-0.94), and the magnitude of the association increased after adjustment of the model for time-varied medication taking (HR: 0.82, 95% CI: 0.79-0.85). The presence of nephropathy had the greatest mediating effect (23.2%) on the association of medication taking and depression.
Conclusion: We demonstrated a steady but modest increase in regular diabetes medication taking over a 9-year period and a significant relationship between medication taking and incident depression in patients with T2D.
(© 2023. International Society of Behavioral Medicine.)

Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2020: estimates of diabetes and its burden in the United States [Internet]. [cited 2021 Feb 2]. Available from: https://www.cdc.gov/diabetes/data/statistics-report/index.html .
American Diabetes Association. 6. Glycemic targets: standards of medical care in diabetes—2021. Diabetes Care. 2021;44 Suppl:S73–84.
American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes—2021. Diabetes Care. 2021;44 Suppl:S111–24.
Khunti K, Seidu S, Kunutsor S, Davies M. Association between adherence to pharmacotherapy and outcomes in type 2 diabetes: a meta-analysis. Diabetes Care. 2017;40:1588–96. (PMID: 10.2337/dc16-192528801474)
Roy T, Lloyd CE. Epidemiology of depression and diabetes: a systematic review. J Affect Disord. 2012;142 Suppl:S8–21.
Moulton CD, Pickup JC, Ismail K. The link between depression and diabetes: the search for shared mechanisms. Lancet Diabetes Endocrinol. 2015;3:461–71. (PMID: 10.1016/S2213-8587(15)00134-525995124)
Kales HC, Maixner DF, Mellow AM. Cerebrovascular disease and late-life depression. Am J Geriatr Psychiatry. 2005;13:88–98. (PMID: 10.1097/00019442-200502000-0000215703317)
Aizenstein HJ, Baskys A, Boldrini M, Butters MA, Diniz BS, Jaiswal MK, et al. Vascular depression consensus report - a critical update. BMC Med. 2016;14:161.
de Groot M, Anderson R, Freedland KE, Clouse RE, Lustman PJ. Association of depression and diabetes complications: a meta-analysis. Psychosom Med. 2001;63:619–30. (PMID: 10.1097/00006842-200107000-0001511485116)
Lin EH, Rutter CM, Katon W, Heckbert SR, Ciechanowski P, Oliver MM, et al. Depression and advanced complications of diabetes: a prospective cohort study. Diabetes Care. 2010;33:264–9. (PMID: 10.2337/dc09-106819933989)
Ismail K, Moulton CD, Winkley K, Pickup JC, Thomas SM, Sherwood RA, et al. The association of depressive symptoms and diabetes distress with glycaemic control and diabetes complications over 2 years in newly diagnosed type 2 diabetes: a prospective cohort study. Diabetologia. 2017;60:2092–102. (PMID: 10.1007/s00125-017-4367-3287760846448879)
Egede LE, Nietert PJ, Zheng D. Depression and all-cause and coronary heart disease mortality among adults with and without diabetes. Diabetes Care. 2005;28:1339–45. (PMID: 10.2337/diacare.28.6.133915920049)
Kan C, Silva N, Golden SH, Rajala U, Timonen M, Stahl D, et al. A systematic review and meta-analysis of the association between depression and insulin resistance. Diabetes Care. 2013;36:480–9. (PMID: 10.2337/dc12-1442233491523554272)
Beurel E, Toups M, Nemeroff CB. The bidirectional relationship of depression and inflammation: double trouble. Neuron. 2020;107:234–56. (PMID: 10.1016/j.neuron.2020.06.002325531977381373)
Taylor WD, Aizenstein HJ, Alexopoulos GS. The vascular depression hypothesis: mechanisms linking vascular disease with depression. Mol Psychiatry. 2013;18:963–74. (PMID: 10.1038/mp.2013.20234394823674224)
Snoek FJ, Bremmer MA, Hermanns N. Constructs of depression and distress in diabetes: time for an appraisal. Lancet Diabetes Endocrinol. 2015;3:450–60. (PMID: 10.1016/S2213-8587(15)00135-725995123)
Nouwen A, Adriaanse MC, van Dam K, Iversen MM, Viechtbauer W, Peyrot M, et al. Longitudinal associations between depression and diabetes complications: a systematic review and meta-analysis. Diabet Med. 2019;36:1562–72.
von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med. 2007;147:573–7.
Gorina Y, Kramarow EA. Identifying chronic conditions in Medicare claims data: evaluating the chronic condition data warehouse algorithm. Health Serv Res. 2011;46:1610-27.
Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi J-C, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43:1130–9. (PMID: 10.1097/01.mlr.0000182534.19832.8316224307)
Leonard CE, Brensinger CM, Nam YH, Bilker WB, Barosso GM, Mangaali MJ, et al. The quality of Medicaid and Medicare data obtained from CMS and its contractors: implications for pharmacoepidemiology. BMC Health Serv Res. 2017;17:304.
Hess LM, Raebel MA, Conner DA, Malone DC. Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmacother. 2006;40:1280–8. (PMID: 10.1345/aph.1H01816868217)
Ho PM, Rumsfeld JS, Masoudi FA, McClure DL, Plomondon ME, Steiner JF, et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med. 2006;166:1836–41. (PMID: 10.1001/archinte.166.17.183617000939)
US Department of Agriculture. 2013 Rural-urban continuum codes [Internet]. [cited 2020 Aug 14]. Available from: https://www.ers.usda.gov/data-products/rural-urban-continuum-codes.aspx .
Lin DY, Wei LJ, Ying Z. Checking the Cox model with cumulative sums of martingale-based residuals. Biometrika. 1993;80:557–72.
Valeri L, VanderWeele TJ. SAS macro for causal mediation analysis with survival data. Epidemiology. 2015;26:e23–4. (PMID: 10.1097/EDE.000000000000025325643116)
Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care. 2004;27:1218–24. (PMID: 10.2337/diacare.27.5.121815111553)
Kirkman MS, Rowan-Martin MT, Levin R, Fonseca VA, Schmittdiel JA, Herman WH, et al. Determinants of adherence to diabetes medications: findings from a large pharmacy claims database. Diabetes Care. 2015;38:604–9. (PMID: 10.2337/dc14-2098255738834370331)
Gillespie CW, Morin PE, Tucker JM, Purvis L. Medication adherence, health care utilization, and spending among privately insured adults with chronic conditions in the United States, 2010–2016. Am J Med. 2020;133:690-704.e19. (PMID: 10.1016/j.amjmed.2019.12.02131987798)
Demoz GT, Wahdey S, Bahrey D, Kahsay H, Woldu G, Niriayo YL, et al. Predictors of poor adherence to antidiabetic therapy in patients with type 2 diabetes: a cross-sectional study insight from Ethiopia. Diabetol Metab Syndr. 2020;12:62. (PMID: 10.1186/s13098-020-00567-7326952327364580)
Lo-Ciganic WH, Donohue JM, Jones BL, Perera S, Thorpe JM, Thorpe CT, et al. Trajectories of diabetes medication adherence and hospitalization risk: a retrospective cohort study in a large state Medicaid program. J Gen Intern Med. 2016;31:1052–60.
Karpati T, Leventer-Roberts M, Feldman B, Cohen-Stavi C, Raz I, Balicer R. Patient clusters based on HbA1c trajectories: a step toward individualized medicine in type 2 diabetes. PLoS One. 2018;13:e0207096.
Lin EH, Katon W, Von Korff M, Rutter C, Simon GE, Oliver M, et al. Relationship of depression and diabetes self-care, medication adherence, and preventive care. Diabetes Care. 2004;27:2154–60. (PMID: 10.2337/diacare.27.9.215415333477)
Marioni RE, Strachan MWJ, Reynolds RM, Lowe GDO, Mitchell RJ, Fowkes FGR, et al. Association between raised inflammatory markers and cognitive decline in elderly people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. Diabetes. 2010;59:710–3. (PMID: 10.2337/db09-116319959761)
Berbudi A, Rahmadika N, Tjahjadi AI, Ruslami R. Type 2 diabetes and its impact on the immune system. Curr Diabetes Rev. 2020;16:442–9. (PMID: 10.2174/1573399815666191024085838)
Maranta F, Cianfanelli L, Cianflone D. Glycaemic control and vascular complications in diabetes mellitus type 2. Adv Exp Med Biol. 2021;1307:129–52. (PMID: 10.1007/5584_2020_51432266607)
Lin LK, Sun Y, Heng BH, Chew DEK, Chong PN. Medication adherence and glycemic control among newly diagnosed diabetes patients. BMJ Open Diabetes Res Care. 2017;5:e000429.
Bouzinova EV, Wiborg O, Aalkjaer C, Matchkov VV. Role of peripheral vascular resistance for the association between major depression and cardiovascular disease. J Cardiovasc Pharmacol. 2015;65:299–307. (PMID: 10.1097/FJC.0000000000000187254698074415957)
Shirazian S, Grant CD, Aina O, Mattana J, Khorassani F, Ricardo AC. Depression in chronic kidney disease and end-stage renal disease: similarities and differences in diagnosis, epidemiology, and management. Kidney Int Rep. 2016;2:94–107. (PMID: 10.1016/j.ekir.2016.09.005293182095720531)
Løfblad L, Hov GG, Åsberg A, Videm V. Inflammatory markers and risk of cardiovascular mortality in relation to diabetes status in the HUNT study. Sci Rep. 2021;11:15644. (PMID: 10.1038/s41598-021-94995-8343413708329190)
Takasaki K, Babazono T, Ishizawa K, Miura J, Uchigata Y. Relationship between diabetic nephropathy and depression: a cross-sectional analysis using the Diabetes Study from the Center of Tokyo Women’s Medical University (DIACET). BMJ Open Diabetes Res care. 2016;4:e000310. (PMID: 10.1136/bmjdrc-2016-000310280741425179608)
Jeong E, Park N, Kim Y, Jeon JY, Chung WY, Yoon D. Temporal trajectories of accompanying comorbidities in patients with type 2 diabetes: a Korean nationwide observational study. Sci Rep. 2020;10:5535. (PMID: 10.1038/s41598-020-62482-1322184987099011)
Kuo YF, Raji MA, Markides KS, Ray LA, Espino DV, Goodwin JS. Inconsistent use of diabetes medications, diabetes complications, and mortality in older mexican americans over a 7-year period: data from the Hispanic established population for the epidemiologic study of the elderly. Diabetes Care. 2003;26:3054–60. (PMID: 10.2337/diacare.26.11.305414578239)

K12 HD052023 United States HD NICHD NIH HHS; P30-AG024832 United States AG NIA NIH HHS; P30-AG024832 United States AG NIA NIH HHS

Keywords: Depression; Diabetes complications; Medication adherence; Type 2 diabetes

Date Created: 20230323 Date Completed: 20240409 Latest Revision: 20240528

20240529

10.1007/s12529-023-10172-3

36952218